EXECUTIVE SUMMARY

The 14th European Meeting on Viral Hepatitis and Co-infection with HIV was held on 25-27 May 2016 at the Roma Eventi Fontana di Trevi Conference Centre and was attended by nearly 300 participants from 40 countries. The meeting gathers a steady international community of researchers and healthcare professionals. The population of this meeting has been stable for a few consecutive years. In 2016 it was almost identical to that of last year.

Professional background of the participants is reflected in the below chart:

![Professional Background Chart]

“A unique forum for improved management and monitoring of HIV and Hepatitis infected patients in Europe, with evidence-based recommendations.”

IMPACT

97% of the respondents indicated that the content of the workshop increased their knowledge, and 83% indicated that the workshop is beneficial for the clinical management of their patients. Furthermore, 86% of the respondents indicated that they intend to incorporate the new information into their daily practice after attending the workshop.

On average, 90% of the respondents indicated that the learning objectives were met.

PROGRAM

The program included 18 invited lectures, 20 oral abstract presentations, two guided poster tours - in addition to the regular poster viewing sessions, a pro-con debate and two roundtable discussions. Ample time was allocated for discussion. Just as last year, 3/4 day was dedicated to Hepatitis C resistance, by way of incorporating the 11th International Workshop on Hepatitis C: Resistance and New Compounds. The presentation of Dr. Francesca Ceccherini, entitled What do we know about RAVs today (delivered as part of the HCV Resistance meeting) received the highest score (an average of 4.7 out of 5) on all categories.

GENERAL MEETING SCORE

93% of the participants rated the meeting experience as excellent/good. 97% would recommend this meeting to their peers and 85% intend to attend next year.

30% indicated good experience by previous editions as one of the main reasons to attend the workshop.

The Organizing Committee and the Organizing Secretariat are pleased with the evaluation results of the 14th edition of this meeting and are looking forward to an even more successful edition in 2017!
# CONTENT

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Summary</td>
<td>2</td>
</tr>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Background</td>
<td>4</td>
</tr>
<tr>
<td>Unique Meeting Features</td>
<td>4</td>
</tr>
<tr>
<td>Target Audience</td>
<td>4</td>
</tr>
<tr>
<td>CME Accreditation</td>
<td>4</td>
</tr>
<tr>
<td>Meeting Objectives</td>
<td>5</td>
</tr>
<tr>
<td>Learning Objectives</td>
<td>5</td>
</tr>
<tr>
<td>Meeting Partners</td>
<td>6</td>
</tr>
<tr>
<td>Commercial Supporters</td>
<td>7</td>
</tr>
<tr>
<td>Organizing Committee</td>
<td>8</td>
</tr>
<tr>
<td>Scientific Committee</td>
<td>10</td>
</tr>
<tr>
<td>Participants’ Feedback</td>
<td>12</td>
</tr>
<tr>
<td>Learning Objectives</td>
<td>12</td>
</tr>
<tr>
<td>General Event Experience</td>
<td>12</td>
</tr>
<tr>
<td>Lectures</td>
<td>13</td>
</tr>
<tr>
<td>Guided Poster Tour</td>
<td>18</td>
</tr>
<tr>
<td>Organization</td>
<td>19</td>
</tr>
<tr>
<td>Publicity</td>
<td>19</td>
</tr>
<tr>
<td>Meeting demographics</td>
<td>20</td>
</tr>
<tr>
<td>Number of Participants</td>
<td>20</td>
</tr>
<tr>
<td>Professional Background</td>
<td>20</td>
</tr>
<tr>
<td>Conclusion</td>
<td>21</td>
</tr>
<tr>
<td>List of Participants</td>
<td>22</td>
</tr>
</tbody>
</table>
INTRODUCTION

This is the evaluation report of the 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, held on 25 - 27 May 2016 at the Roma Eventi - Fontana di Trevi Conference Center. The Organizing Committee and the Organizing Secretariat highly value the opinion of the participants in order to further improve the quality of the workshop. Participants were asked to complete an evaluation form to share their opinion on several subjects. Average response rate to this survey was 50%.

BACKGROUND

The European HIV and Hepatitis meeting was started 14 years ago with the objective to provide infectious disease clinicians and clinical virologists involved in clinical practice and research with an opportunity to share data and discuss their clinical application. Originally the focus was on HIV but over the years with the developments in the viral hepatitis field HCV and HBV were added. The focus for each of these infections is on treatment of mono-infection.

In the last decade the meeting has been able to capture a constant group of leading clinicians and researchers from Europe. As such, this meeting is the only European platform where infectious disease doctors and clinical virologists get together on an annual basis to have more in depth discussions regarding the developments in antiviral therapy.

FORMAT

This 2.5 day international, abstract-driven scientific and educational workshop consisted of invited lectures, round-table discussions, abstract-driven presentations and poster sessions. In order to ascertain an interactive workshop setting, much time was allocated to discussions. From 2015, the meeting incorporates the International Workshop on Hepatitis C: Resistance and New Compounds as a half-day program on Day 2.

UNIQUE MEETING FEATURES

The European Meeting on HIV & Hepatitis – Treatment Strategies & Antiviral Drug Resistance is a unique European platform for clinicians and clinical virologists to discuss the latest developments in antiviral therapy for HIV, HCV and HBV and for translating them into new treatment strategies to further improve clinical care.

TARGET AUDIENCE

- Clinicians involved in daily care of individuals infected with HIV, HCV and HBV;
- Scientists involved in antiviral drug development;
- Researchers;
- Post-graduate students.

CME ACCREDITATION

The 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance was designated for a maximum of 15 hours of European external CME credits.
MEETING OBJECTIVES

- To gather professionals in the field of infectious diseases and clinical virology in an interactive workshop setting;
- To provide a platform for presentation and discussion of the latest developments in the field of antiviral drug development;
- To map all current studies and results;
- To translate new data to treatment guidelines;
- To educate clinicians on how to best implement current and new drugs in clinical practice.

LEARNING OBJECTIVES

After participating in this activity, the participants will:

- Have a thorough knowledge of the most recent results in drug development (including most recent clinical trials results) for HIV, HCV and HBV;
- Be able to integrate the latest scientific results into daily clinical care to improve the quality of life of HIV / Hepatitis infected individuals;
- Recognize the future challenges in screening, monitoring and diagnosis of HIV and of HCV or HBV infected patients.
Financial support for the *14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance* was provided by the following companies:

**TITANIUM LEVEL**

ViiV Healthcare

**GOLD LEVEL**

Gilead
ORGANIZING COMMITTEE

CARLO FEDERICO Perno, MD, PHD
University of Rome “Tor Vergata”, Rome, Italy

JONATHAN Schapiro, MD
Sheba Medical Center, Tel Aviv, Israel

Anne - mieke Vandamme, PHD
Katholieke Universiteit Leuven, Belgium

Linos VandeKerckhove, MD, PHD
University Hospital of Gent, Belgium

Jens Verheyen, MD
University Clinic Essen, Germany

Annemarie Wensing, MD, PHD
University Medical Centre Utrecht, the Netherlands

Stefan Zeuzem, MD
J.W. Goethe University Hospital, Frankfurt, Germany
SCIENTIFIC COMMITTEE

Jan Albert, MD .................................. IMPI Karolinska Institute, Sweden
Claudia Balotta, MD .......................... University of Milan, Italy
Carlos Beltran, MD ........................... Chilean AIDS Group, Chile
Marina Bobkova, PhD ....................... Ivanovsky Institute of Virology, Russia
Ricardo Camacho, PhD ...................... Hospital Egas Moniz, Portugal
Bonaventura Clotet, MD, PhD ............. Irsi Caixa Foundation, Barcelona, Spain
Rolf Kaiser, PhD ............................... University of Cologne, Germany
Leon Kostrikis, PhD ......................... University of Cyprus, Cyprus
Clive Loveday, PhD ........................... ICVC Charitable Trust, Clinical Virology, United Kingdom
Jens Lundgren, MD ........................... National University Hospital & University of Copenhagen, Denmark
Anne-Genevieve Marcelin, PharmD, PhD .... UPMC, France
Claus Nielsen, MD, PhD ..................... Statens Serum Institut, Denmark
Monique Nijhuis, PhD ....................... University Medical Center Utrecht, The Netherlands
Dimitris Paraskevis, PhD ................... University of Athens, Medical School, Greece
Mario Poljak, MD, PhD ...................... Institute for Microbiology and Immunology, Slovenia
Elisabeth Puchhammer, MD ................ University of Vienna, Austria
Jürgen Rockstroh, MD ........................ University of Bonn, Germany
Christophe Rodriguez, MD ................ Hôpital Henri Mondor, France
Gary Rubin, MD ............................... University of Toronto, Canada
Jean-Claude Schmit, MD, PhD .......... Centre Hospitalier de Luxembourg & CRP-Santé, Luxembourg
Rob Schuurman, PhD ....................... University Medical Centre Utrecht, The Netherlands
Anders Sönnerborg, MD, PhD .......... Karolinska Institut, Sweden
Vincent Soriano, MD, PhD ................ Hospital Carlos III, Spain
Janusz Stanczak, PhD ........................ University of Warsaw, Poland
Adrian Streinu - Cercel, MD, PhD ....... National Institute of Inf. Diseases “Prof. Dr. Matei Bals”, Romania
Hauke Walter, MD ............................ Medizinisches Labor Dr. Berg, Germany
Maurizio Zazzi, PhD .......................... University of Siena, Italy
Fabien Zoulim, MD, PhD ................. INSERM, France
COMMITTEES

11TH INTERNATIONAL WORKSHOP ON HEPATITIS C: RESISTANCE AND NEW COMPOUNDS

ORGANIZING COMMITTEE

CHARLES BOUCHER, MD, PHD
Erasmus Medical Center, Rotterdam, the Netherlands

STÉPHANE CHEVALIEZ, PHARMD, PHD
Hôpital Henri Mondor, Université Paris XII, Paris, France

ANITA HOWE, PHD
British Columbia Center for Excellence for HIV/AIDS, Canada

STEFAN ZEUZEM, MD
J.W. Goethe University Hospital, Frankfurt, Germany

SCIENTIFIC COMMITTEE

Ralf Bartenschlager, PhD ................... University of Heidelberg, Germany
Francesca Ceccherini-Silverstein, PhD ........ University of Rome, Italy
Raffaele De Francesco, PhD ............... Fondazione INGM, Italy
Jeffrey Glenn, MD, PhD ..................... Stanford University, USA
Eric Hughes, MD, PhD ..................... Bristol-Myers Squibb Company, USA
George Kukolj, PhD ......................... Boehringer Ingelheim, Canada
Michael Manns, MD ......................... Medical School of Hannover, Germany
Isabel Najera, PhD .......................... Roche (Palo Alto), USA
Jean-Michel Pawlotsky, MD, PhD ....... Hôpital Henri Mondor, France
Chris Petropoulos, PhD .................... Monogram Biosciences, USA
Tami Pilot-Matias, PhD ..................... Abbvie, USA
Charles Rice, PhD .......................... Rockefeller University, USA
Celia Schiffer, PhD .......................... University of Massachusetts, USA
Robert Schooley, MD ....................... University of California, USA
David Standring, PhD ......................
Mark Sulkowski, MD ....................... Johns Hopkins University, USA
Bill Symonds, PharmD ..................... Roivant Sciences, USA
Takaji Wakita MD, PhD ................... National Institute of Infectious Diseases, Japan
PARTICIPANTS’ FEEDBACK

INTENT TO CHANGE

<table>
<thead>
<tr>
<th></th>
<th>(Strongly) agree</th>
<th>Neutral</th>
<th>(Strongly) disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>The lectures have increased my knowledge of treatment strategies and antiviral drug resistance</td>
<td>97%</td>
<td>3%</td>
<td>0%</td>
</tr>
<tr>
<td>This program is beneficial for the clinical management of my patients</td>
<td>83%</td>
<td>17%</td>
<td>0%</td>
</tr>
<tr>
<td>I intend to incorporate the new information into the care of my patients</td>
<td>86%</td>
<td>9%</td>
<td>5%</td>
</tr>
</tbody>
</table>

The following factor(s) might prevent me from implementing the gained knowledge:

- My patient population might not be appropriate for the implementation. 22%
- My current office and practice systems might not accommodate the changes. 33%
- My patients might have trouble complying with these changes/strategies. 11%
- The medications/procedures discussed might not be available for my patients. 22%
- These changes might be too time consuming. 11%

LEARNING OBJECTIVES

<table>
<thead>
<tr>
<th></th>
<th>(Strongly) agree</th>
<th>Average</th>
<th>(Strongly) disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>After completing this activity, the participants will:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Have a thorough knowledge of the most recent results in drug development [including most recent clinical trials results] for HIV, HCV and HBV</td>
<td>93%</td>
<td>7%</td>
<td>0%</td>
</tr>
<tr>
<td>Be able to integrate the latest scientific results into daily clinical care to improve the quality of life of HIV / Hepatitis infected individuals</td>
<td>86%</td>
<td>14%</td>
<td>0%</td>
</tr>
</tbody>
</table>

GENERAL EVENT EXPERIENCE

<table>
<thead>
<tr>
<th></th>
<th>Excellent /very much agree</th>
<th>Average/neutral</th>
<th>Fair /disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall event experience</td>
<td>93%</td>
<td>7%</td>
<td>0%</td>
</tr>
<tr>
<td>Opportunity of networking</td>
<td>93%</td>
<td>7%</td>
<td>0%</td>
</tr>
<tr>
<td>Content of the conference</td>
<td>93%</td>
<td>7%</td>
<td>0%</td>
</tr>
<tr>
<td>Number of invited lectures versus abstracts</td>
<td>79%</td>
<td>21%</td>
<td>0%</td>
</tr>
<tr>
<td>Was Hep C resistance a valuable addition to the meeting?</td>
<td>93%</td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td>Time allocation for discussion</td>
<td>100%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Time allocation per presentation</td>
<td>93%</td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td>No commercial bias (product selling) perceived</td>
<td>85%</td>
<td>11%</td>
<td>4%</td>
</tr>
<tr>
<td>I would recommend this meeting to my peers</td>
<td>97%</td>
<td>3%</td>
<td>0%</td>
</tr>
<tr>
<td>I plan to attend this meeting next year</td>
<td>85%</td>
<td>15%</td>
<td>0%</td>
</tr>
</tbody>
</table>
## LECTURES

### WEDNESDAY 25 MAY

### Session 1: Early ARV treatment: start early, but not too early

<table>
<thead>
<tr>
<th>Lecturer</th>
<th>Title</th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carlo Federico Perno, MD, PhD, University of Rome “Tor Vergata”, Italy</td>
<td>HIV in Europe 2020 – what will it look like?</td>
<td>99%</td>
<td>1%</td>
<td>0%</td>
</tr>
<tr>
<td>Georg Behrens, MD, PhD, Medical School Hannover, Germany</td>
<td>Life-long therapy</td>
<td>91%</td>
<td>9%</td>
<td>0%</td>
</tr>
</tbody>
</table>

### Abstract-driven presentations:

- **Potent Activity of GS-9883, a Novel Unboosted HIV-1 Integrase Strand Transfer Inhibitor (INSTI), Against Patient Isolates with INSTI-Resistance**

<table>
<thead>
<tr>
<th>Lecturer</th>
<th>Title</th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>K. White O_01</td>
<td></td>
<td>85%</td>
<td>15%</td>
<td>0%</td>
</tr>
</tbody>
</table>

- **Dolutegravir plus Rilpivirine in cART-Experienced Subjects: a cohort study**

<table>
<thead>
<tr>
<th>Lecturer</th>
<th>Title</th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>G. Sterrantino O_02</td>
<td></td>
<td>72%</td>
<td>18%</td>
<td>10%</td>
</tr>
</tbody>
</table>

- **Dolutegravir plus Ritonavir-Boosted Darunavir in Highly cART-Experienced Subjects**

<table>
<thead>
<tr>
<th>Lecturer</th>
<th>Title</th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>G. Sterrantino O_03</td>
<td></td>
<td>73%</td>
<td>15%</td>
<td>12%</td>
</tr>
</tbody>
</table>

### Session 2: Spread of HIV drug resistance

### Abstract-driven presentations:

- **Next generation sequencing in routine HIV-1 resistance diagnostic - frequency of additional resistance relevant mutations in 2% and 1% population proportions**

<table>
<thead>
<tr>
<th>Lecturer</th>
<th>Title</th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>R. Ehret O_04</td>
<td></td>
<td>78%</td>
<td>19%</td>
<td>3%</td>
</tr>
</tbody>
</table>
PARTICIPANTS’ FEEDBACK

3 Transmission of HIV drug resistance mutations varies regionally in Europe
M. Hofstra O_05

<table>
<thead>
<tr>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>88%</td>
<td>9%</td>
</tr>
<tr>
<td>Relevance</td>
<td>77%</td>
<td>17%</td>
</tr>
</tbody>
</table>

Patients with pre-existent NRTI- and NNRTI-resistance have a higher risk to lose virological suppression under tenofovir/emtricitabine/rilpivirine single tablet regimen
D. Di Carlo O_06

<table>
<thead>
<tr>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>83%</td>
<td>11%</td>
</tr>
<tr>
<td>Relevance</td>
<td>72%</td>
<td>18%</td>
</tr>
</tbody>
</table>

Antiviral Activity of Tenofovir Alafenamide (TAF) against HIV-1 Subtypes and Emergence of K65R
C. Callebaut O_07

<table>
<thead>
<tr>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>79%</td>
<td>19%</td>
</tr>
<tr>
<td>Relevance</td>
<td>66%</td>
<td>24%</td>
</tr>
</tbody>
</table>

Session 3: Abstract session - HBV-related

HBV Cure (Educational lecture in collaboration with ESAR)
Massimo Levrero, MD, University of Rome “La Sapienza”, Italy

<table>
<thead>
<tr>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>97%</td>
<td>3%</td>
</tr>
<tr>
<td>Relevance</td>
<td>70%</td>
<td>18%</td>
</tr>
<tr>
<td>Performance</td>
<td>90%</td>
<td>5%</td>
</tr>
</tbody>
</table>

Clinical impact of vaccine-escape HBsAg mutants in HBV-infected patients: high rate of atypical serological profiles and increased level of viremia and transaminases
R. Salpini O_08

<table>
<thead>
<tr>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>79%</td>
<td>16%</td>
</tr>
<tr>
<td>Relevance</td>
<td>63%</td>
<td>21%</td>
</tr>
</tbody>
</table>

Immunosuppression-driven HBV Reactivation in Patients with Resolved HBV Infection Correlates with a Relevant Risk of Evolution Towards Active Chronic Infection and Death
A. Battisti O_09

<table>
<thead>
<tr>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>74%</td>
<td>22%</td>
</tr>
<tr>
<td>Relevance</td>
<td>62%</td>
<td>24%</td>
</tr>
</tbody>
</table>

HBsAg immune-escape Mutations and Stop-Codons, Circulating among European HBV-chronically infected patients can impact on HBV transmission and disease progression
L. Colagrossi O_10

<table>
<thead>
<tr>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>73%</td>
<td>22%</td>
</tr>
<tr>
<td>Relevance</td>
<td>59%</td>
<td>24%</td>
</tr>
</tbody>
</table>

Session 4: Implementation of PrEP in Europe

Roadblocks to implementation
Pep Coll, MD, Irsi Caixa Foundation, Barcelona, Spain

<table>
<thead>
<tr>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>89%</td>
<td>10%</td>
</tr>
<tr>
<td>Relevance</td>
<td>74%</td>
<td>18%</td>
</tr>
<tr>
<td>Performance</td>
<td>88%</td>
<td>10%</td>
</tr>
</tbody>
</table>
### PARTICIPANTS’ FEEDBACK

#### Two cases of HIV drug resistance arising after PrEP

**Richard Harrigan, MD**, BC Centre for Excellence in HIV/AIDS, Canada

<table>
<thead>
<tr>
<th></th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>89%</td>
<td>9%</td>
<td>3%</td>
</tr>
<tr>
<td>Relevance</td>
<td>75%</td>
<td>12%</td>
<td>13%</td>
</tr>
<tr>
<td>Performance</td>
<td>91%</td>
<td>9%</td>
<td>0%</td>
</tr>
</tbody>
</table>

#### Community perspective

**Rebekah Webb, MA**, EATG, United Kingdom

<table>
<thead>
<tr>
<th></th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>90%</td>
<td>9%</td>
<td>1%</td>
</tr>
<tr>
<td>Relevance</td>
<td>75%</td>
<td>14%</td>
<td>11%</td>
</tr>
<tr>
<td>Performance</td>
<td>95%</td>
<td>4%</td>
<td>1%</td>
</tr>
</tbody>
</table>

#### Round Table discussion: experiences with implementation of PrEP

Moderator: Charles Boucher

<table>
<thead>
<tr>
<th></th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>93%</td>
<td>6%</td>
<td>1%</td>
</tr>
<tr>
<td>Relevance</td>
<td>76%</td>
<td>14%</td>
<td>11%</td>
</tr>
</tbody>
</table>

### THURSDAY 26 MAY

#### HIV attachment inhibitors

**Thomas Klimkait, PhD**, University of Basel, Switzerland

<table>
<thead>
<tr>
<th></th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>96%</td>
<td>4%</td>
<td>0%</td>
</tr>
<tr>
<td>Relevance</td>
<td>78%</td>
<td>15%</td>
<td>7%</td>
</tr>
<tr>
<td>Performance</td>
<td>96%</td>
<td>4%</td>
<td>0%</td>
</tr>
</tbody>
</table>

#### Session 5: Special session - maintenance therapy

1. **Maintenance Therapy - What is known**

   **Esteban Martinez, MD, PhD**, University of Barcelona, Spain

<table>
<thead>
<tr>
<th></th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>100%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Relevance</td>
<td>87%</td>
<td>6%</td>
<td>6%</td>
</tr>
<tr>
<td>Performance</td>
<td>97%</td>
<td>3%</td>
<td>0%</td>
</tr>
</tbody>
</table>

2. **Maintenance Therapy - What is the scientific / virological rationale**

   **Charles Boucher, MD, PhD**, Erasmus Medical Center, the Netherlands

<table>
<thead>
<tr>
<th></th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>97%</td>
<td>3%</td>
<td>0%</td>
</tr>
<tr>
<td>Relevance</td>
<td>84%</td>
<td>10%</td>
<td>6%</td>
</tr>
<tr>
<td>Performance</td>
<td>97%</td>
<td>3%</td>
<td>0%</td>
</tr>
</tbody>
</table>

3. **Maintenance Therapy - What is the Future**

   **Jonathan Schapiro, MD**, Sheba Medical Center, Israel

<table>
<thead>
<tr>
<th></th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>100%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Relevance</td>
<td>94%</td>
<td>3%</td>
<td>3%</td>
</tr>
<tr>
<td>Performance</td>
<td>100%</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>
### 11th International Workshop on Hepatitis C: Resistance and New Compounds

**Session 1:**

<table>
<thead>
<tr>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
<th>Evaluation</th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / Poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Host-acting broad-spectrum antiviral drugs from nature</td>
<td>Juana Díez, PhD</td>
<td>Universitat Pompeu Fabra, Spain</td>
<td></td>
<td>Outstanding</td>
<td></td>
<td></td>
</tr>
<tr>
<td>How do we test for HCV RAVs (technology-based presentation)</td>
<td>Anita Howe, PhD</td>
<td>British Columbia Center for Excellence for HIV/AIDS, Canada</td>
<td></td>
<td>Excellent / Good</td>
<td>Average</td>
<td>Fair / Poor</td>
</tr>
<tr>
<td>Do we need surveillance for DAA resistance: how to implement it</td>
<td>Stephanie Popping, MD</td>
<td>Erasmus MC, the Netherlands</td>
<td></td>
<td>Excellent / Good</td>
<td>Average</td>
<td>Fair / Poor</td>
</tr>
</tbody>
</table>

**Session 2:**

<table>
<thead>
<tr>
<th>Title</th>
<th>Speaker</th>
<th>Evaluation</th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / Poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>What do we know about RAVs today</td>
<td>Francesca Ceccherini - Silberstein, PhD</td>
<td></td>
<td>Excellent / Good</td>
<td>Average</td>
<td>Fair / Poor</td>
</tr>
<tr>
<td>Abstract-driven presentations:</td>
<td></td>
<td></td>
<td>Outstanding</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Substantial presence of natural NS3, NS5A and NS5B HCV-resistance in real practice, and their impact on direct-acting antiviral treatment in genotypes 1-4</td>
<td>V. Cento O_11</td>
<td></td>
<td>Excellent / Good</td>
<td>Average</td>
<td>Fair / Poor</td>
</tr>
<tr>
<td>Characterization of Resistance-Associated Variants at baseline and failure of All-Oral Antiviral Therapy of Hepatitis C</td>
<td>A. Lai O_12</td>
<td></td>
<td>Excellent / Good</td>
<td>Average</td>
<td>Fair / Poor</td>
</tr>
</tbody>
</table>

**Session 3:**

<table>
<thead>
<tr>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
<th>Evaluation</th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / Poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>What do we need to know about RAVs clinically</td>
<td>Stefan Zeuzem, MD</td>
<td>JW Goethe University Hospital, Germany</td>
<td></td>
<td>Outstanding</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PARTICIPANTS’ FEEDBACK

Abstract-driven presentations:

Virological failures to DAA in real life show frequent resistance associated variants and may require re-treatment with unconventional regimens

<table>
<thead>
<tr>
<th></th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>89%</td>
<td>11%</td>
<td>0%</td>
</tr>
<tr>
<td>Relevance</td>
<td>88%</td>
<td>4%</td>
<td>8%</td>
</tr>
</tbody>
</table>

V. C. Di Maio O_13

Treatment emergent variants to combined direct antiviral agents therapy against hepatitis C virus

<table>
<thead>
<tr>
<th></th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>93%</td>
<td>7%</td>
<td>0%</td>
</tr>
<tr>
<td>Relevance</td>
<td>88%</td>
<td>8%</td>
<td>4%</td>
</tr>
</tbody>
</table>

F. Garcia O_14

Total HIV DNA increases in lymphomonocytes of HCV/HIV co-infected patients during and after DAA treatment

<table>
<thead>
<tr>
<th></th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>76%</td>
<td>19%</td>
<td>5%</td>
</tr>
<tr>
<td>Relevance</td>
<td>75%</td>
<td>10%</td>
<td>15%</td>
</tr>
</tbody>
</table>

I. Abbate O_15

FRIDAY 27 MAY

Session 6: Remaining challenges in the optimal use of boosted PIs

Pro-con Debate: Role of PIs in first line therapy

<table>
<thead>
<tr>
<th></th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI are obsolete in first line</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anna Maria Geretti, MD, PhD, University of Liverpool, UK</td>
<td>100%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Relevance</td>
<td>92%</td>
<td>4%</td>
<td>4%</td>
</tr>
<tr>
<td>Performance</td>
<td>100%</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI remain important option for first line</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Linos Vandekerckhove, MD, PhD, University Hospital Gent, Belgium</td>
<td>100%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Relevance</td>
<td>92%</td>
<td>4%</td>
<td>4%</td>
</tr>
<tr>
<td>Performance</td>
<td>88%</td>
<td>12%</td>
<td>0%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improving PI drug resistance scores</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jens Verheyen, MD, University Clinic Essen, Germany</td>
<td>96%</td>
<td>4%</td>
<td>0%</td>
</tr>
<tr>
<td>Relevance</td>
<td>87%</td>
<td>4%</td>
<td>9%</td>
</tr>
<tr>
<td>Performance</td>
<td>100%</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>

Session 7: HIV cure strategies

Diagnostic Assays

<table>
<thead>
<tr>
<th></th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Javier Martinez Picado, PhD, Irsi Caixa Foundation, Barcelona, Spain</td>
<td>100%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Relevance</td>
<td>86%</td>
<td>9%</td>
<td>5%</td>
</tr>
<tr>
<td>Performance</td>
<td>100%</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>
## PARTICIPANTS’ FEEDBACK

### Abstract-driven presentations:

<table>
<thead>
<tr>
<th>Presentation</th>
<th>Opinion</th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ex vivo determination of stem cell transplantation graft-versus-HIV reservoir effects</strong> L. Hogan O_16</td>
<td>Interesting</td>
<td>90%</td>
<td>5%</td>
<td>5%</td>
</tr>
<tr>
<td>Relevance</td>
<td>74%</td>
<td>11%</td>
<td>15%</td>
<td></td>
</tr>
<tr>
<td><strong>Clonal Integration Site Frequency and Replication Competent Virus in Patients on ART</strong> L. Vandekerckhove O_17</td>
<td>Interesting</td>
<td>89%</td>
<td>11%</td>
<td>0%</td>
</tr>
<tr>
<td>Relevance</td>
<td>76%</td>
<td>12%</td>
<td>12%</td>
<td></td>
</tr>
</tbody>
</table>

### Boston Project

**Timothy Henrich, MD, UCSF, USA**

<table>
<thead>
<tr>
<th>Opinion</th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>95%</td>
<td>5%</td>
<td>0%</td>
</tr>
<tr>
<td>Relevance</td>
<td>82%</td>
<td>9%</td>
<td>9%</td>
</tr>
<tr>
<td>Performance</td>
<td>95%</td>
<td>5%</td>
<td>0%</td>
</tr>
</tbody>
</table>

### Abstract-driven presentations:

<table>
<thead>
<tr>
<th>Presentation</th>
<th>Opinion</th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Viral dynamics and post-mortem analysis of HIV-1 Reservoir after Allogeneic Transplantation using Stem Cells with a nonfunctional CCR5 (CCR5-d32) co-receptor</strong> K. Bosman O_18</td>
<td>Interesting</td>
<td>89%</td>
<td>11%</td>
<td>0%</td>
</tr>
<tr>
<td>Relevance</td>
<td>67%</td>
<td>22%</td>
<td>11%</td>
<td></td>
</tr>
<tr>
<td><strong>Treatment of HIV and acute myeloid leukemia by allogeneic CCR5-d32 blood stem cell transplantation</strong> E. Knops O_19</td>
<td>Interesting</td>
<td>89%</td>
<td>11%</td>
<td>0%</td>
</tr>
<tr>
<td>Relevance</td>
<td>61%</td>
<td>28%</td>
<td>11%</td>
<td></td>
</tr>
<tr>
<td><strong>Breakthrough of preexisting X4-tropic HIV after allogeneic stem-cell transplantation</strong> J. Verheyen O_20</td>
<td>Interesting</td>
<td>89%</td>
<td>11%</td>
<td>0%</td>
</tr>
<tr>
<td>Relevance</td>
<td>72%</td>
<td>17%</td>
<td>11%</td>
<td></td>
</tr>
</tbody>
</table>

### Panel Discussion

**Members**: Javier Martinez Picado, Timothy Henrich, Rolf Kaiser, Monique Nijhuis and Annemarie Wensing

<table>
<thead>
<tr>
<th>Opinion</th>
<th>Excellent / Good</th>
<th>Average</th>
<th>Fair / poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interesting</td>
<td>94%</td>
<td>6%</td>
<td>0%</td>
</tr>
<tr>
<td>Relevance</td>
<td>69%</td>
<td>25%</td>
<td>6%</td>
</tr>
</tbody>
</table>

## GUIDED POSTER TOUR

<table>
<thead>
<tr>
<th>Opinion</th>
<th>(Very much) agree</th>
<th>Neutral</th>
<th>(Very much) disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guided poster tour was a valuable addition</td>
<td>83%</td>
<td>13%</td>
<td>4%</td>
</tr>
<tr>
<td>The posters selected for the tour were relevant</td>
<td>88%</td>
<td>8%</td>
<td>4%</td>
</tr>
</tbody>
</table>
PARTICIPANTS’ FEEDBACK

ORGANIZATION

<table>
<thead>
<tr>
<th>Service</th>
<th>Excellent/good</th>
<th>Average</th>
<th>Fair/poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Content of electronic announcements</td>
<td>86%</td>
<td>8%</td>
<td>6%</td>
</tr>
<tr>
<td>Frequency of electronic announcements</td>
<td>84%</td>
<td>14%</td>
<td>3%</td>
</tr>
<tr>
<td>Information on conference website</td>
<td>74%</td>
<td>20%</td>
<td>6%</td>
</tr>
<tr>
<td>Online registration process</td>
<td>76%</td>
<td>19%</td>
<td>5%</td>
</tr>
<tr>
<td>Online abstract submission process</td>
<td>84%</td>
<td>12%</td>
<td>4%</td>
</tr>
<tr>
<td>Meeting venue</td>
<td>84%</td>
<td>16%</td>
<td>0%</td>
</tr>
<tr>
<td>Food &amp; Beverage</td>
<td>89%</td>
<td>8%</td>
<td>3%</td>
</tr>
<tr>
<td>Audiovisuals</td>
<td>78%</td>
<td>14%</td>
<td>8%</td>
</tr>
<tr>
<td>Onsite logistics</td>
<td>86%</td>
<td>11%</td>
<td>3%</td>
</tr>
<tr>
<td>Service level of Conference Secretariat</td>
<td>89%</td>
<td>11%</td>
<td>0%</td>
</tr>
</tbody>
</table>

PUBLICITY

Attention was drawn to this meeting by:

- VE website: 19%
- VE email announcement: 16%
- VE invitation letter: 3%
- Flyer at other meetings: 1%
- Invite from the industry: 2%
- Invite by faculty members: 12%
- Colleague/word of mouth: 17%
- I am returning participant: 30%

Influenced to attend this meeting by:

- Meeting description: 19%
- Scientific program: 37%
- Opportunity to meet with colleagues: 19%
- Experience from previous editions: 14%
- Location: 6%
- Reg. fee: 2%
- CME Accreditation: 3%
MEETING DEMOGRAPHICS

NUMBER OF PARTICIPANTS

In 2015 this meeting had 287 participants from 40 countries. Largest groups were from Italy (85), Germany (16), Belgium (16) and Russia (16).

The geographical distribution of participants is as follows:

Australia 2  Estonia 1  Mexico 5  Spain 10  
Bangladesh 2  Finland 4  Montenegro 2  Sweden 4  
Belarus 1  France 6  Nepal 1  Switzerland 2  
Belgium 16  Germany 16  Norway 6  The Netherlands 14  
Brazil 1  Greece 4  Poland 4  Turkey 3  
Bulgaria 1  Hungary 2  Portugal 12  Ukraine 11  
Canada 10  Israel 2  Romania 1  United Kingdom 11  
Chile 5  Italy 85  Russia 16  USA 6  
Cyprus 1  Latvia 2  Saudi Arabia 2  
Czech Republic 1  Lithuania 5  Serbia 2  
Denmark 5  Luxembourg 2  Slovenia 1  

PROFESSIONAL BACKGROUND

Main activity

- Clinician 31%
- Researcher 35%
- Other 16%

Mainly employed by:

- University 41%
- Hospital 28%
- NGO 2%
- Other 11%

Area of expertise:

- HIV 47%
- Hepatitis 35%
- ID 15%
- Other 3%
CONCLUSION

The overall opinion of the meeting was very positive, as can be deducted from the above scores. Participants were satisfied with the scientific content of the workshop as well as with the logistics and the format of the program. The Organizing Committee and the Organizing Secretariat are very pleased with the evaluation results of this workshop. The success and importance of this workshop have underlined the need for continuation. The 15th edition of the European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance is scheduled to take place on 7 - 9 May 2017 in Rome, Italy.
<table>
<thead>
<tr>
<th>Last name, name</th>
<th>Institute</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbate, Isabella</td>
<td>Istituto Nazionale per le Malattie Infettive “Lazzaro Spallanzani” Roma</td>
<td>Italy</td>
</tr>
<tr>
<td>Abreu, Ricardo</td>
<td>HPHispano-Matosinhos</td>
<td>Portugal</td>
</tr>
<tr>
<td>Acevedo Muñoz, William</td>
<td>Hospital de Enfermedades infecciosas Dr Lucio Cordova</td>
<td>Chile</td>
</tr>
<tr>
<td>Adams, Philipp</td>
<td>Luxembourg institute of health</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>Afani, Alejandro</td>
<td>University of Chile</td>
<td>Chile</td>
</tr>
<tr>
<td>Ahmed, Nursarat</td>
<td>Gazi Medical college and Hospital</td>
<td>Bangladesh</td>
</tr>
<tr>
<td>Aladdin, Hassan</td>
<td>Gilead</td>
<td>Denmark</td>
</tr>
<tr>
<td>Albert, Jan</td>
<td>Karolinska Institutet</td>
<td>Sweden</td>
</tr>
<tr>
<td>Albini, Laura</td>
<td>Gilead Sciences</td>
<td>Italy</td>
</tr>
<tr>
<td>Alexiev, Ivailo</td>
<td>Nat. Center of Infectious and Parasitic Diseases</td>
<td>Bulgaria</td>
</tr>
<tr>
<td>Ali, Batool</td>
<td>East Jeddah Hospital</td>
<td>Saudi Arabia</td>
</tr>
<tr>
<td>Alteri, Claudia</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Amato, Maurizio</td>
<td>ViiV Healthcare</td>
<td>Italy</td>
</tr>
<tr>
<td>Andre, Gomes</td>
<td>Hospital Garcia de Orta</td>
<td>Portugal</td>
</tr>
<tr>
<td>Antonucci, Francesco</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Aragri, Marianna</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Armenia, Daniele</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Avanzi, Valeria Miranda</td>
<td>Universidade Federal do Paraná</td>
<td>Brazil</td>
</tr>
<tr>
<td>Bak, Narin</td>
<td>Royal Adelaide Hospital</td>
<td>Australia</td>
</tr>
<tr>
<td>Bakken Kran, Anne-Marte</td>
<td>Oslo University Hospital</td>
<td>Norway</td>
</tr>
<tr>
<td>Bakó, Fruzsina</td>
<td>St.István és St.László Kórház</td>
<td>Hungary</td>
</tr>
<tr>
<td>Baldanti, Fausto</td>
<td>IRCCS Policlinico S. Matteo</td>
<td>Italy</td>
</tr>
<tr>
<td>Bandera, Alessandra</td>
<td>San Gerardo Hospital</td>
<td>Italy</td>
</tr>
<tr>
<td>Bang, Didi</td>
<td>Statens Serum Institut</td>
<td>Denmark</td>
</tr>
<tr>
<td>Bannert, Norbert</td>
<td>Robert Koch-Institut</td>
<td>Germany</td>
</tr>
<tr>
<td>Barbaliscia, Silvia</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Baril, Jean-Guy</td>
<td>Clinique du Quartier Latin</td>
<td>Canada</td>
</tr>
<tr>
<td>Bartolini, Barbara</td>
<td>Istituto Nazionale per le Malattia Infettive “Lazzaro Spallanzani” Roma</td>
<td>Italy</td>
</tr>
<tr>
<td>Battisti, Arianna</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Behrens, Georg</td>
<td>Medical School Hannover</td>
<td>Germany</td>
</tr>
<tr>
<td>Beloukas, Apostolos</td>
<td>Institute of Infection and Global Health</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Beltrán, Carlos</td>
<td>Chilean AIDS Group</td>
<td>Chile</td>
</tr>
<tr>
<td>Berno, Giulia</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Bertoli, Ada</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Berzina, Ilze</td>
<td>Riga Eastern Clinical University Hospital, Infectology Center</td>
<td>Latvia</td>
</tr>
<tr>
<td>Bobkova, Marina</td>
<td>Ivanovsky Institute of Virology Gamaleya Center for Epidemiology and Microbiology</td>
<td>Russia</td>
</tr>
<tr>
<td>Boccuto, Adele</td>
<td>UNIVERSITA’ DI SIENA- Policlinico Le Scotte</td>
<td>Italy</td>
</tr>
<tr>
<td>Bocket, Laurence</td>
<td>CHRU Lille</td>
<td>France</td>
</tr>
<tr>
<td>Boggia, Nadia</td>
<td>ViiV Healthcare</td>
<td>Italy</td>
</tr>
<tr>
<td>Name</td>
<td>Institution</td>
<td>Country</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Bon, Isabella</td>
<td>Università di Bologna</td>
<td>Italy</td>
</tr>
<tr>
<td>Bondar, Borys</td>
<td>AbbVie</td>
<td>Ukraine</td>
</tr>
<tr>
<td>Bosman, Kobus</td>
<td>University Medical Center Utrecht UMCU</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Boucher, Charles</td>
<td>Erasmus Medical Center</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Bozhok, Halya</td>
<td>Kirovograd AIDS Center</td>
<td>Ukraine</td>
</tr>
<tr>
<td>Braun, Patrick</td>
<td>Insto GmbH</td>
<td>Germany</td>
</tr>
<tr>
<td>Brunetta, Jason</td>
<td>Maple Leaf Medical Clinic</td>
<td>Canada</td>
</tr>
<tr>
<td>Bruzzo, Bianca</td>
<td>University of Genoa</td>
<td>Italy</td>
</tr>
<tr>
<td>Caligiuri, Patrizia</td>
<td>Ircs Azienda Univ. Osp. San Martino</td>
<td>Italy</td>
</tr>
<tr>
<td>Callebaut, Christian</td>
<td>Gilead</td>
<td>USA</td>
</tr>
<tr>
<td>Callegaro, Annapaola</td>
<td>Ospedali Riuniti di Bergamo Hospital Papa Giovanni XXIII</td>
<td>Italy</td>
</tr>
<tr>
<td>Camacho, Ricardo</td>
<td>KU Leuven</td>
<td>Belgium</td>
</tr>
<tr>
<td>Cardoso, Luis</td>
<td>Gilead Sciences</td>
<td>Portugal</td>
</tr>
<tr>
<td>Carioti, Luca</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Carta, Stefania</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Carvalho, Margarida Maria</td>
<td>CH Vila Nova Gaia</td>
<td>Portugal</td>
</tr>
<tr>
<td>Ceccherini-Silberstein, Francesca</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Cento, Valeria</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Chen, Alan</td>
<td>The Ohio State University</td>
<td>USA</td>
</tr>
<tr>
<td>Chernova, Oksana</td>
<td>Tolyatti City Clinical Hospital No. 5</td>
<td>Russia</td>
</tr>
<tr>
<td>Chevaliez, Stéphane</td>
<td>Hôpital Henri Mondor, Université Paris XII</td>
<td>France</td>
</tr>
<tr>
<td>Chulanov, Vladimir</td>
<td>Central Research Institute of Epidemiology</td>
<td>Russia</td>
</tr>
<tr>
<td>Cid Silva, Purificacion</td>
<td>Gilead Sciences</td>
<td>Spain</td>
</tr>
<tr>
<td>Cinite, Ingrida</td>
<td>GlaxoSmithKline</td>
<td>Latvia</td>
</tr>
<tr>
<td>Circhetta, Simona</td>
<td>Gilead Sciences</td>
<td>Italy</td>
</tr>
<tr>
<td>Colagrossi, Luna</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Coll, Pep</td>
<td>Hospital Universitari Germans Trias i Pujol</td>
<td>Spain</td>
</tr>
<tr>
<td>Craxi, Antonio</td>
<td>DIBIMIS, University of Palermo</td>
<td>Italy</td>
</tr>
<tr>
<td>Cuomo, Nunzia</td>
<td>Aorn ospedali dei colli - Cotugno</td>
<td>Italy</td>
</tr>
<tr>
<td>Cuypers, Lize</td>
<td>Rega Institute for Medical Research</td>
<td>Belgium</td>
</tr>
<tr>
<td>Damele, Francesco</td>
<td>Janssen</td>
<td>Italy</td>
</tr>
<tr>
<td>D'Angelo, Giulia Maria</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>De Jorge, Rocio</td>
<td>ViV Healthcare</td>
<td>Spain</td>
</tr>
<tr>
<td>De Luca, Andrea</td>
<td>University of Catania Azienda Ospedaliera Senese</td>
<td>Italy</td>
</tr>
<tr>
<td>Debasieux, Laurent</td>
<td>ULB-Erasmus</td>
<td>Belgium</td>
</tr>
<tr>
<td>Demecheleer, Els</td>
<td>University Hospital Gent</td>
<td>Belgium</td>
</tr>
<tr>
<td>Demetriades, Ioannis</td>
<td>Larnaca General Hospital</td>
<td>Cyprus</td>
</tr>
<tr>
<td>Deppere, Melissa</td>
<td>UZ Brussel</td>
<td>Belgium</td>
</tr>
<tr>
<td>Devaux, Carole</td>
<td>CRP-Santé</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>Di Carlo, Daniele</td>
<td>Sapienza - Università di Roma</td>
<td>Italy</td>
</tr>
<tr>
<td>Di Carlo, Domenico</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Di Maio, Velia Chiara</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Diez, Juana</td>
<td>University Pompeu Fabra</td>
<td>Spain</td>
</tr>
<tr>
<td>Name</td>
<td>Institution</td>
<td>Country</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Dorenberg, Dagny Haug</td>
<td>Norwegian Institute of Public Health</td>
<td>Norway</td>
</tr>
<tr>
<td>Döring, Matthias</td>
<td>Max Planck Institute for Informatics</td>
<td>Germany</td>
</tr>
<tr>
<td>Dressler, Stephan</td>
<td>EATG - European AIDS Treatment Group</td>
<td>Belgium</td>
</tr>
<tr>
<td>Dupanovic, Branica</td>
<td>Institute of Public Health Montenegro</td>
<td>Montenegro</td>
</tr>
<tr>
<td>Dvorakova, Katerina</td>
<td>GSK</td>
<td>Czech Republic</td>
</tr>
<tr>
<td>Dyda, Tomasz</td>
<td>Hospital for Infectious Diseases</td>
<td>Poland</td>
</tr>
<tr>
<td>Ehret, Robert</td>
<td>BAG MVZ mb AG &amp; Kollegen GbR Medizinisches Labor Dr. Berg</td>
<td>Germany</td>
</tr>
<tr>
<td>Fabeni, Lavinia</td>
<td>I.N.M.I. Lazzaro Spallanzani</td>
<td>Italy</td>
</tr>
<tr>
<td>Fabietti, Giulio</td>
<td>Viiv Healthcare</td>
<td>Italy</td>
</tr>
<tr>
<td>Falasca, Francesca</td>
<td>Sapienza - Università di Roma</td>
<td>Italy</td>
</tr>
<tr>
<td>Farabegoli, Patrizia</td>
<td>AUSL Cesena</td>
<td>Italy</td>
</tr>
<tr>
<td>Fedele, Valentina</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Feinberg, Joshua</td>
<td>Copenhagen University Hospital Rigshospitalet</td>
<td>Denmark</td>
</tr>
<tr>
<td>Fernandes, Magda</td>
<td>H.Sra.Oliveira-Guimarães</td>
<td>Portugal</td>
</tr>
<tr>
<td>Ferreira, Mafalda</td>
<td>Instituto Superior de Ciências da Saúde Egas Moniz</td>
<td>Portugal</td>
</tr>
<tr>
<td>Ferrer, Pablo</td>
<td>Universidad de Chile</td>
<td>Chile</td>
</tr>
<tr>
<td>Ferrinho, Diogo</td>
<td>Gilead Sciences Europe</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Fimian, Caterina</td>
<td>Policlinico Umberto I</td>
<td>Italy</td>
</tr>
<tr>
<td>Fini, Vanessa</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Floe, Reinhardt</td>
<td>GlaxoSmithKline</td>
<td>Norway</td>
</tr>
<tr>
<td>Fokam, Joseph</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Fonager, Jannik</td>
<td>Statens Serum Institut</td>
<td>Denmark</td>
</tr>
<tr>
<td>Forbici, Federica</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Franzese, Sonia</td>
<td>Gilead Sciences</td>
<td>Italy</td>
</tr>
<tr>
<td>Fraser, Chris</td>
<td>Cool Aid Clinic</td>
<td>Canada</td>
</tr>
<tr>
<td>Galizzi, Nadia</td>
<td>Università Vita-Salute - Ospedale San Raffaele Milano</td>
<td>Italy</td>
</tr>
<tr>
<td>Garcia, Federico</td>
<td>CHU Granada; Centro PTS-San Cecilio. Inst Inv Biosanitaria Ibs-Granada.</td>
<td>Spain</td>
</tr>
<tr>
<td>Gardziuliene, Gabija</td>
<td>Glaxo Smith Kline</td>
<td>Lithuania</td>
</tr>
<tr>
<td>Gaytán Martínez, Jesús Enrique</td>
<td>National Medical Center &quot;La Raza&quot;, Mexico</td>
<td>Mexico</td>
</tr>
<tr>
<td>Geretti, Anna Maria</td>
<td>University of Liverpool Institute of Infection and Global Health</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Giannella, Sara</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Giannini, Alessia</td>
<td>UNIVERSITA' DI SIENA - Policlinico Le Scotte</td>
<td>Italy</td>
</tr>
<tr>
<td>Gomes, Perpetua</td>
<td>Centro Hospitalar de Lisboa Ocidental</td>
<td>Portugal</td>
</tr>
<tr>
<td>Gori, Caterina</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Gunduz, Alper</td>
<td>Sisli Efthal Training and Research Hospital</td>
<td>Turkey</td>
</tr>
<tr>
<td>Haartsen, Maxim</td>
<td>Viiv Healthcare</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Hammer, Janniche</td>
<td>Gilead Sciences</td>
<td>Norway</td>
</tr>
<tr>
<td>Harrigan, Richard</td>
<td>BC Centre for Excellence in HIV/AIDS</td>
<td>Canada</td>
</tr>
<tr>
<td>Hauser, Andrea</td>
<td>Robert Koch-Institut</td>
<td>Germany</td>
</tr>
<tr>
<td>Hawkes, Jennifer</td>
<td>Northern Health</td>
<td>Canada</td>
</tr>
<tr>
<td>Henrich, Timothy</td>
<td>University of California, San Francisco</td>
<td>USA</td>
</tr>
</tbody>
</table>
Hofstra, Marije  
University Medical Center Utrecht UMCU  
The Netherlands

Hogan, Louise  
UCSF  
USA

Howe, Anita  
Vancouver Coastal Health Authority  
Canada

Jevtovic, Djordje  
Institute for Infectious and Tropical Diseases  
Serbia

Kaiser, Rolf  
University of Cologne  
Germany

Kanestrøm, Anita  
Norwegian Institute of Public Health  
Norway

Kapusta, Margaryta  
Mykolaiv Regional State Administration  
Ukraine

Kausas, Aidas  
Siauliai County Hospital  
Lithuania

Kazennova, Elena  
Ivanovsky Institute of Virology Gamaleya Center for Epidemiology and Microbiology  
Russia

Khromova, Irina  
Republican Center for Prevention and Control of AIDS and Infectious Diseases  
Russia

Klein, Alex  
Mount Sinai Hospital  
Canada

Klimkait, Thomas  
University of Basel  
Switzerland

Knezevic, Olgica  
Institute of Public Health Montenegro  
Montenegro

Knops, Elena  
University of Cologne  
Germany

Koenig, Bettina  
Abbvie  
Germany

Kostaki, Evangelina  
University of Athens  
Greece

Kwa, David  
Onze Lieve Vrouwe Gasthuis  
The Netherlands

Kyrychenko, Tatjana  
Ukrainian Medical Stomatological Academy  
Ukraine

Kyryliuk, Olga  
Abbvie  
Ukraine

Laga, Vita  
Ivanovsky Institute of Virology Gamaleya Center for Epidemiology and Microbiology  
Russia

Lai, Alessia  
University of Milan  
Italy

Lapovok, Ilya  
Central Research Institute for Epidemiology  
Russia

Lennerstrand, Johan  
Uppsala University  
Sweden

Lettinga, Kamilla  
Onze Lieve Vrouwe Gasthuis  
The Netherlands

Levrero, Massimo  
University La Sapienza  
Italy

Lichtner, Miriam  
Sapienza University of Rome  
Italy

Liitsola, Kirsi  
National Institute for Health and Welfare  
Finland

Lipsi, Maria Rosaria  
OSPEDALI RIUNITI - FOGGIA  
Italy

Loginova, Tetyana  
Narceological Hospital Socialtherapy  
Ukraine

Longo, Serena  
Università di Bologna  
Italy

Louagie, Philippe  
ViiV Healthcare  
Belgium

Louis, Isabelle  
University Bordeaux Inserm U897- Isped  
France

Loveday, Clive  
ICVC Charitable Trust  
United Kingdom

Lübke, Nadine  
Institute of Virology  
Germany

Lynn, Amber  
Alberta Health Services  
Canada

Maigren Steffensson, Catharina  
Gilead Sciences Sweden AB  
Sweden

Marascio, Nadia  
University "Magna Graecia"  
Italy

Martínez Picado, Javier  
Fundacio irsiCaixa  
Spain

Martinez, Esteban  
Hospital Clinic Barcelona  
Spain

Martiushova, Inna  
Tula Regional Hospital  
Russia

Mascia, Claudia  
Sapienza - Università di Roma  
Italy
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mata-Marín, José Antonio</td>
<td>Centro Medico Nacional “La Raza”</td>
<td>Mexico</td>
</tr>
<tr>
<td>Matsiyeuskaya, Natallia</td>
<td>Grodno State Medical University</td>
<td>Belarus</td>
</tr>
<tr>
<td>Matulionyte, Raimonda</td>
<td>Vilnius University</td>
<td>Lithuania</td>
</tr>
<tr>
<td>Mazzi, Laura</td>
<td>Sapienza - Università di Roma</td>
<td>Italy</td>
</tr>
<tr>
<td>Meini, Genny</td>
<td>Università degli Studi di Siena</td>
<td>Italy</td>
</tr>
<tr>
<td>Micheli, Valeria</td>
<td>University Hospital L. Sacco</td>
<td>Italy</td>
</tr>
<tr>
<td>Möikänen, Tomi</td>
<td>GlaxoSmithKline</td>
<td>Finland</td>
</tr>
<tr>
<td>Mor, Orna</td>
<td>Sheba Medical Center</td>
<td>Israel</td>
</tr>
<tr>
<td>Mortier, Virginie</td>
<td>University Hospital Gent</td>
<td>Belgium</td>
</tr>
<tr>
<td>Mudrikova, Tatiana</td>
<td>University Medical Center Utrecht UMCU</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Nielsen, Emil Eik</td>
<td>Copenhagen University Hospital Rigshospitalet</td>
<td>Denmark</td>
</tr>
<tr>
<td>Nieman, An-Emmie</td>
<td>St Elisabeth Ziekenhuis</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Nijhuis, Monique</td>
<td>University Medical Center Utrecht UMCU</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Ojha, Chet</td>
<td>Government of Nepal</td>
<td>Nepal</td>
</tr>
<tr>
<td>Oliveira, Celia</td>
<td>Hospital de Aveiro</td>
<td>Portugal</td>
</tr>
<tr>
<td>Oosterlaken, Tom</td>
<td>Hologic</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Palandri, Lucia</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Paolucci, Stefania</td>
<td>IRCCS Policlinico S. Matteo</td>
<td>Italy</td>
</tr>
<tr>
<td>Paraskevis, Dimitrios</td>
<td>University of Athens</td>
<td>Greece</td>
</tr>
<tr>
<td>Parczewski, Milosz</td>
<td>Pomeranian Medical University</td>
<td>Poland</td>
</tr>
<tr>
<td>Paredes, Roger</td>
<td>IrsiCaixa Foundation</td>
<td>Spain</td>
</tr>
<tr>
<td>Paricio, Antonio</td>
<td>Hospital Francisco De Borja De Gandia</td>
<td>Australia</td>
</tr>
<tr>
<td>Paul, Miriam</td>
<td>Macquarie University</td>
<td>Portugal</td>
</tr>
<tr>
<td>Pereira, Rui</td>
<td>Hospital de Faro</td>
<td>Italy</td>
</tr>
<tr>
<td>Perno, Carlo-Federico</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Pesic Pavlovic, Ivana</td>
<td>Clinical Center of Serbia</td>
<td>Serbia</td>
</tr>
<tr>
<td>Petrovska, Olena</td>
<td>Zaporizhya AIDS center</td>
<td>Ukraine</td>
</tr>
<tr>
<td>Petry, Ralph</td>
<td>Abbvie Deutschland GmbH &amp; Co KG</td>
<td>Germany</td>
</tr>
<tr>
<td>Piermatteo, Lorenzo</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Pineda-Peña, Andrea Clementia</td>
<td>KU Leuven</td>
<td>Belgium</td>
</tr>
<tr>
<td>Pirazolli, Antonella</td>
<td>ViiV Healthcare</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Poljak, Mario</td>
<td>University of Ljubljana Medical Faculty</td>
<td>Slovenia</td>
</tr>
<tr>
<td>Pompei, Marco</td>
<td>Merck Sharp and Dohme</td>
<td>Belgium</td>
</tr>
<tr>
<td>Popping, Stephanie</td>
<td>Erasmus Medical Center</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Poretskova, Elena</td>
<td>R-Pharm</td>
<td>Russia</td>
</tr>
<tr>
<td>Posthumus-Plantinga, Alice</td>
<td>Virology Education</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Poveda, Eva</td>
<td>INIBIC-Complejo Hospitalario Universitario de A Coruña</td>
<td>Spain</td>
</tr>
<tr>
<td>Poveda, Jean-Dominique</td>
<td>Laboratoire CERBA</td>
<td>France</td>
</tr>
<tr>
<td>Prodanova, Kseniia</td>
<td>Center of prevention and control of AIDS</td>
<td>Russia</td>
</tr>
<tr>
<td>Quercia, Romina</td>
<td>ViiV Healthcare</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Rahman, Nawshad Muhammad</td>
<td>Gazi Medical college and Hospital</td>
<td>Bangladesh</td>
</tr>
<tr>
<td>Wahidur</td>
<td>San Martino Hospital University of Genoa</td>
<td>Italy</td>
</tr>
<tr>
<td>Name</td>
<td>Institution</td>
<td>Country</td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Robinson, Chris</td>
<td>Gilead Sciences</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Rodriguez-Diaz, Roberto</td>
<td>Instituto Nacional de Ciencias Médicas y Nutrición</td>
<td>Mexico</td>
</tr>
<tr>
<td>Rogatto, Felipe</td>
<td>Gilead Sciences</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Roger Schmeltz, Julien</td>
<td>Gilead Sciences</td>
<td>France</td>
</tr>
<tr>
<td>Rosas, Antonio</td>
<td>Pharma Investi de Chile Ss. A.</td>
<td>Chile</td>
</tr>
<tr>
<td>Rossetti, Barbara</td>
<td>Clinic of Infectious Diseases, AOUS</td>
<td>Italy</td>
</tr>
<tr>
<td>Roxo, Joao</td>
<td>HOSPITAL DOS CAPUCHOS</td>
<td>Portugal</td>
</tr>
<tr>
<td>Rozera, Gabriella</td>
<td>Istituto Nazionale per le Malattie Infettive &quot;Lazzaro Spallanzani&quot; Roma</td>
<td>Italy</td>
</tr>
<tr>
<td>Rubin, Gary</td>
<td>University of Toronto</td>
<td>Canada</td>
</tr>
<tr>
<td>Ruelle, Jean</td>
<td>UC Louvain</td>
<td>Belgium</td>
</tr>
<tr>
<td>Ruggiero, Tina</td>
<td>Amedeo di Savoia Hospital</td>
<td>Italy</td>
</tr>
<tr>
<td>Sabinina, Olena</td>
<td>Poltava AIDS center</td>
<td>Ukraine</td>
</tr>
<tr>
<td>Sakalauskiene, Ugne</td>
<td>Central Prison Hospital</td>
<td>Lithuania</td>
</tr>
<tr>
<td>Saladini, Francesco</td>
<td>University of Siena</td>
<td>Italy</td>
</tr>
<tr>
<td>Salpini, Romina</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Santangelo, Rosaria</td>
<td>Catholic University Del Sacro Cuore Institute of Clinical Infectious Diseases</td>
<td>Italy</td>
</tr>
<tr>
<td>Santoro, Maria</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Sarmometov, Evgenii</td>
<td>Perm Regional Centre for the Fight against AIDS and infectious diseases</td>
<td>Russia</td>
</tr>
<tr>
<td>Sayan, Murat</td>
<td>Kocaeli University</td>
<td>Turkey</td>
</tr>
<tr>
<td>Schaffer, Sven</td>
<td>Hologic</td>
<td>Germany</td>
</tr>
<tr>
<td>Schapiro, Jonathan</td>
<td>Sheba Medical Center</td>
<td>Israel</td>
</tr>
<tr>
<td>Schütze, Marcel</td>
<td>MVZ mir medizinisches Infektiologiezentrum Berlin AG</td>
<td>Germany</td>
</tr>
<tr>
<td>Scutari, Rossana</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Shevchenko, Olga</td>
<td>Dnipropetrovsk Medical Academy</td>
<td>Ukraine</td>
</tr>
<tr>
<td>Shostakovych-Koretskaya, Liudmyla</td>
<td>Dnipropetrovsk Medical Academy</td>
<td>Ukraine</td>
</tr>
<tr>
<td>Sikut, Rein</td>
<td>GlaxoSmithKline</td>
<td>Estonia</td>
</tr>
<tr>
<td>Silva, Luis</td>
<td>H. Fernando Fonseca</td>
<td>Portugal</td>
</tr>
<tr>
<td>Sönnerborg, Anders</td>
<td>Karolinska Institutet</td>
<td>Sweden</td>
</tr>
<tr>
<td>Sorbo, Maria Chiara</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Stanczak, Janusz</td>
<td>Hospital for Infectious Diseases</td>
<td>Poland</td>
</tr>
<tr>
<td>Starikova, Irina</td>
<td>Republican Center for Prevention and Control of AIDS and Infectious Diseases</td>
<td>Russia</td>
</tr>
<tr>
<td>Stasishkis, Tatiana</td>
<td>Republican Center for Prevention and Control of AIDS and Infectious Diseases</td>
<td>Russia</td>
</tr>
<tr>
<td>Stazi, Francesca</td>
<td>University of Rome Tor Vergata</td>
<td>Italy</td>
</tr>
<tr>
<td>Stefanova, Ina</td>
<td>ViV Healthcare</td>
<td>Canada</td>
</tr>
<tr>
<td>Stene-Johansen, Kathrine</td>
<td>Norwegian Institute of Public Health</td>
<td>Norway</td>
</tr>
<tr>
<td>Stepanova, Elena</td>
<td>Republican Center for Prevention and Control of AIDS and Infectious Diseases</td>
<td>Russia</td>
</tr>
<tr>
<td>Sterrantino, Gaetana</td>
<td>Azienda Ospedaliera Universitaria Careggi</td>
<td>Italy</td>
</tr>
<tr>
<td>Sticchi, Laura</td>
<td>University of Genoa</td>
<td>Italy</td>
</tr>
<tr>
<td>Name</td>
<td>Institution/Company</td>
<td>Country</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>---------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Sutinen, Jussi</td>
<td>Helsinki University Hospital</td>
<td>Finland</td>
</tr>
<tr>
<td>Tau, Pamela</td>
<td>University Hospital L. Sacco</td>
<td>Italy</td>
</tr>
<tr>
<td>Tavares, Francisca</td>
<td>Gilead Sciences</td>
<td>Portugal</td>
</tr>
<tr>
<td>Tudor, Ana Maria</td>
<td>Institute for Infectious Disease M. Bals Matei</td>
<td>Romania</td>
</tr>
<tr>
<td>Ujhelyi, Eszter</td>
<td>St.István és St.László Kórház</td>
<td>Hungary</td>
</tr>
<tr>
<td>Underwood, Mark</td>
<td>GlaxoSmithKline</td>
<td>USA</td>
</tr>
<tr>
<td>Vandamme, Anne-Mieke</td>
<td>Katholieke Univ. Leuven Rega Institute for Medical</td>
<td>Belgium</td>
</tr>
<tr>
<td></td>
<td>Research</td>
<td></td>
</tr>
<tr>
<td>Vandekerckhove, Linos</td>
<td>Universitair Ziekenhuis Gent UZ</td>
<td>Belgium</td>
</tr>
<tr>
<td>Vandercam, Bernard</td>
<td>UCLouvain</td>
<td>Belgium</td>
</tr>
<tr>
<td>Vanhouteghem, Hilde</td>
<td>AZ Maria Middelares</td>
<td>Belgium</td>
</tr>
<tr>
<td>Varna, Klaidas</td>
<td>Abbvie</td>
<td>Lithuania</td>
</tr>
<tr>
<td>Vatteroni, Marialinda</td>
<td>Azienda Ospedaliiera Universitaria Pisana</td>
<td>Italy</td>
</tr>
<tr>
<td>Verheyen, Jens</td>
<td>Universitätsklinikum Essen</td>
<td>Germany</td>
</tr>
<tr>
<td>Vicenti, Ilaria</td>
<td>University of Siena</td>
<td>Italy</td>
</tr>
<tr>
<td>Villa, Giovanni</td>
<td>University of Liverpool Institute of Infection and Global</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Health</td>
<td></td>
</tr>
<tr>
<td>Vincenti, Donatella</td>
<td>Istituto Nazionale per le Malattie Infettive “Lazzaro</td>
<td>Italy</td>
</tr>
<tr>
<td></td>
<td>Spallanzani” Roma</td>
<td></td>
</tr>
<tr>
<td>Vuorte, Juha</td>
<td>Gilead Sciences Finland</td>
<td>Finland</td>
</tr>
<tr>
<td>Wali, Ghassan</td>
<td>King Faisal Specialist Hospital and Research Centre</td>
<td>Saudi Arabia</td>
</tr>
<tr>
<td>Walter, Hauke</td>
<td>EATG european aids treatment group</td>
<td>Germany</td>
</tr>
<tr>
<td>Webb, Rebekah</td>
<td>MC/groep MC Zuiderzee</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Weijer, Sebastiaan</td>
<td>Anahuac University, Medicine school, Mexico city, Mexico</td>
<td>Mexico</td>
</tr>
<tr>
<td>Weiser Smeke, Ariane Estrella</td>
<td>University Medical Center Utrecht UMCU</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Wensing, Annemarie</td>
<td>Gilead Sciences</td>
<td>USA</td>
</tr>
<tr>
<td>White, Kirsten</td>
<td>Institute of Virology, University Hospital of Essen</td>
<td>Germany</td>
</tr>
<tr>
<td>Widera, Marek</td>
<td>National Public Health Institution of Turkey</td>
<td>Turkey</td>
</tr>
<tr>
<td>Yalcinkaya Kezban Tulay, KezbanTulay</td>
<td>Regional Clinical Hospital of Infectious Diseases</td>
<td>Russia</td>
</tr>
<tr>
<td>Yurchuk, Sergey</td>
<td>Hospital for Infectious Diseases</td>
<td>Poland</td>
</tr>
<tr>
<td>Zabek, Piotr</td>
<td>INMI L Spallanzani</td>
<td>Italy</td>
</tr>
<tr>
<td>Zaccarelli, Mauro</td>
<td>Kharkiv AIDS center</td>
<td>Ukraine</td>
</tr>
<tr>
<td>Zadorozhna, Kateryna</td>
<td>Oncology Reference Centre</td>
<td>Italy</td>
</tr>
<tr>
<td>Zanussi, Stefania</td>
<td>University of Siena</td>
<td>Italy</td>
</tr>
<tr>
<td>Zazzi, Maurizio</td>
<td>JW Goethe University Hospital</td>
<td>Germany</td>
</tr>
<tr>
<td>Zeuzem, Stefan</td>
<td>University of Basel</td>
<td>Switzerland</td>
</tr>
</tbody>
</table>